- Home
- CSTL vs AXGN Comparison
CSTL vs AXGN Comparison
Compare CSTL & AXGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- AXGN
- Stock Information
- Founded
- CSTL 2007
- AXGN N/A
- Country
- CSTL United States
- AXGN United States
- Employees
- CSTL N/A
- AXGN N/A
- Industry
- CSTL Medical Specialities
- AXGN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CSTL Health Care
- AXGN Health Care
- Exchange
- CSTL Nasdaq
- AXGN Nasdaq
- Market Cap
- CSTL 456.2M
- AXGN 538.3M
- IPO Year
- CSTL 2019
- AXGN N/A
- Fundamental
- Price
- CSTL $19.46
- AXGN $11.36
- Analyst Decision
- CSTL Strong Buy
- AXGN Strong Buy
- Analyst Count
- CSTL 6
- AXGN 6
- Target Price
- CSTL $37.67
- AXGN $23.83
- AVG Volume (30 Days)
- CSTL 462.3K
- AXGN 676.1K
- Earning Date
- CSTL 08-04-2025
- AXGN 08-07-2025
- Dividend Yield
- CSTL N/A
- AXGN N/A
- EPS Growth
- CSTL N/A
- AXGN N/A
- EPS
- CSTL N/A
- AXGN N/A
- Revenue
- CSTL $347,083,000.00
- AXGN $194,520,000.00
- Revenue This Year
- CSTL N/A
- AXGN $18.08
- Revenue Next Year
- CSTL $1.36
- AXGN $16.15
- P/E Ratio
- CSTL N/A
- AXGN N/A
- Revenue Growth
- CSTL 38.43
- AXGN 18.81
- 52 Week Low
- CSTL $15.45
- AXGN $7.33
- 52 Week High
- CSTL $35.84
- AXGN $21.00
- Technical
- Relative Strength Index (RSI)
- CSTL 55.41
- AXGN 57.00
- Support Level
- CSTL $18.18
- AXGN $9.35
- Resistance Level
- CSTL $20.63
- AXGN $11.19
- Average True Range (ATR)
- CSTL 0.77
- AXGN 0.50
- MACD
- CSTL 0.07
- AXGN 0.28
- Stochastic Oscillator
- CSTL 57.36
- AXGN 97.72
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About AXGN Axogen Inc.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.